natgillin/translations-raw huggingface dataset:
These include optical coherence tomography (OCT), ophthalmoscopy (foveal reflex), colour vision test (Roth 28-hue) and full-field ERG. 
Med te preiskave sodijo optična koherentna tomografija (OCT), oftalmoskopija (fovealni refleks), testiranje barvnega vida (Rothovo z 28 barvami) in ERG celotnega vidnega polja.
Repeated administration in the same eye is not recommended. 
Ponovnega dajanja v isto oko ne priporočamo.
The patient had a decrease in BCVA of 21 ETDRS letters from baseline that returned to within 9 letters of baseline at the end of the study. 
Bolnik je imel poslabšanje BCVA za 21 ETDRS črk glede na izhodišče, ki se je ob koncu študije vrnila na 9 črk od izhodišča.
Ethnicity Experience is limited in groups other than Caucasians. 
Izkušnje pri etničnih skupinah, ki niso belci, so omejene.
The adverse reactions with a reasonable possibility of causal relationship to the injection procedure or JETREA are listed by MedDRA system organ class and frequency using the following convention: very common (≥ 1/10); common (≥ 1/100 to < 1/10); uncommon (≥ 1/1,000 to < 1/100); rare (≥ 1/10,000 to < 1/1,000); very rare (< 1/10,000) and not known (cannot be estimated from the available data). 
razumno mogoča, so navedeni po organskih sistemih MedDRA in pogostnosti po naslednjem dogovoru: zelo pogosti (≥1/10); pogosti (≥1/100 do <1/10); občasni (≥1/1.000 do <1/100); redki (≥1/10.000 do <1/1.000); zelo redki (<1/10.000); neznana (ni mogoče oceniti iz razpoložljivih podatkov).
It is unknown whether JETREA is excreted in human milk. 
Ni znano, ali se zdravilo JETREA izloča v materino mleko.
Repeated administration of JETREA in the same eye has not been adequately studied and is therefore not recommended. 
Ponavljajoče dajanje Ponavljajoče dajanje zdravila JETREA v isto oko ni zadosti preučeno, zato ga ne priporočamo.
Days Post-Injection 
št. dni po injiciranju
Do not use this medicine after the expiry date which is stated on the label and on the carton after EXP. 
Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na nalepki in škatli poleg oznake EXP. Rok uporabnosti zdravila se izteče na zadnji dan navedenega meseca.
Any persistence or progression of macular hole should be treated according to usual practice. 
Morebitno trdovratno navzočnost ali napredovanje foramna makule je treba zdraviti v skladu z običajno prakso.
Tell your doctor/ophthalmologist if you are taking, have recently taken or might take any other medicines. 
Obvestite svojega zdravnika/oftalmologa, če jemljete, ste pred kratkim jemali ali pa boste morda začeli jemati katero koli drugo zdravilo.
Inform your doctor/ophthalmologist if you have had an injection of a medicine into the eye recently. 
Obvestite svojega zdravnika/oftalmologa, če ste pred kratkim v oko prejeli injekcijo zdravila.
If you have any further questions on the use of this medicine, ask your doctor/ophthalmologist. 
Če imate dodatna vprašanja o uporabi zdravila, se posvetujte s svojim zdravnikom/oftalmologom.
In study TG-MV-014, a sub-set of 40 patients receiving JETREA systematically underwent ERG testing; the ERG changes which had developed in 16 out of 40 patients resolved in the majority of patients (13 out of 16). 
V študiji TG-MV-014 so pri podskupini 40 bolnikov, ki so prejemali zdravilo JETREA, opravili sistematično testiranje ERG; spremembe ERG, ki so se pojavile pri 16 od 40 bolnikov, so izzvenele pri večini bolnikov (pri 13 od 16).
In a clinical study in patients scheduled for vitrectomy receiving 0.125 mg JETREA (corresponding to a theoretical start concentration of 29 µg/mL vitreous), mean ocriplasmin activity was 9% of theoretical start concentration 2-4 hours after injection and below the lower level of quantification at 7 days. 
V klinični študiji pri bolnikih, načrtovanih za vitrektomijo, ki so prejeli 0,125 mg zdravila JETREA (kar ustreza teoretični začetni koncentraciji 29 µg/ml steklovine), je bila srednja aktivnost okriplazmina 9 % teoretične začetne koncentracije 2-4 ure po injiciranju, 7. dan pa pod spodnjo ravnijo merljivosti.
Lens subluxation was observed in the 3 species at ocriplasmin concentrations at or above 41 µg/mL vitreous, a concentration above the intended clinical concentration of 29 µg/mL. 
Subluksacijo leče so opazili pri 3 vrstah pri koncentracijah okriplazmina 41 µg/ml steklovine ali več, kar je koncentracija nad predvideno klinično koncentracijo 29 µg/ml.
The effect of ocriplasmin (particularly in inducing resolution of vitreomacular adhesion or causing total posterior vitreous detachment [PVD]) is reduced in subjects with an epiretinal membrane (ERM) or a diameter of VMA > 1500 microns (see section 5.1). 
Učinek okriplazmina (zlasti pri induciranju odprave vitreomakularne adhezije ali povzročitvi popolnega posteriornega odstopa steklovine [PVD - Posterior Vitreous Detachment]) je manjši pri bolnikih z epiretinalno membrano (ERM) ali premerom vitreomakularne adhezije >1500 mikronov (glejte poglavje 5.1).
However, chemical and physical in-use stability of unopened product in the original carton protected from light has been demonstrated for up to 8 hours when stored below 25 °C. 
Kemijska in fizikalna stabilnost neodprtega zdravila med uporabo je dokazana do 8 ur, če je zdravilo shranjeno v originalni škatli, zaščiteno pred svetlobo in pri temperaturi do 25 °C.
See section 4.4 for instructions on post-injection monitoring. 
Glejte poglavje 4.4 za navodila za spremljanje po injiciranju.
The efficacy of JETREA was demonstrated in 2 pivotal multicentre, randomised, double-masked, placebo-controlled, 6-month studies in patients with VMT. 
Učinkovitost zdravila JETREA je bila dokazana v 2 osrednjih multicentričnih, randomiziranih, dvojno slepih, s placebom kontroliranih, 6-mesečnih študijah pri bolnikih z vitreomakularno trakcijo.
In rabbits and monkeys, the incidence of vitreous cell infiltrates tended to resolve over time. 
Pri kuncih in opicah se je incidenca infiltratov celic v steklovini čez čas zmanjšala.
There are no data for the use of JETREA in pregnant women. 
Podatkov o uporabi zdravila JETREA pri nosečnicah ni.
ERG changes were not predictive of negative outcomes in terms of visual acuity; visual acuity improved or was maintained in 15 out of 16 patients compared to baseline. 
S spremembami ERG ni mogoče napovedati negativnega izida ostrine vida; v primerjavi z izhodiščem se je ostrina vida izboljšala oziroma je ostala enaka pri 15 od 16 bolnikov.
3 years when stored in a freezer (-20 °C ± 5 °C). 
3 leti pri shranjevanju v zamrzovalniku (-20 °C ± 5 °C).
The visual acuity decrease had resolved by the end of the studies for the majority of JETREA patients (80.6%) but there were some patients who had not recovered despite vitrectomy. 
Do konca študije je zmanjšanje ostrine vida izzvenelo pri večini bolnikov, zdravljenih z zdravilom JETREA (80,6 %), pri nekaterih pa kljub vitrektomiji izboljšanja ni bilo.
Patients should be instructed to report symptoms suggestive of intraocular inflammation/infection or any other visual or ocular symptoms without delay. 
Bolnike je treba poučiti, da nemudoma poročajo o simptomih, ki bi lahko kazali na intraokularno vnetje/okužbo, ali o drugih simptomih, povezanih z vidom ali očesom.
The intravitreal injection procedure should be carried out under controlled aseptic conditions, which include the use of surgical hand disinfection, sterile gloves, a sterile drape, a sterile eyelid speculum (or equivalent) and the availability of sterile paracentesis (if required). 
Postopek intravitrealnega injiciranja mora biti izveden v nadzorovanih aseptičnih pogojih, ki vključujejo uporabo kirurške dezinfekcije rok, sterilnih rokavic, sterilnega pregrinjala, sterilnega spekuluma za veke (ali drugega ustreznega pripomočka) in možnost sterilne paracenteze (če je potrebno).
All adverse reactions were ocular. 
Vsi neželeni učinki so bili okularni.
Information about storage and the time to use Jetrea once it has been thawed and diluted are described in the section intended for healthcare professionals only. 
Informacije o shranjevanju in času, v katerem je treba uporabiti zdravilo Jetrea potem, ko je bilo odmrznjeno in razredčeno, so opisane v poglavju, ki je namenjeno samo zdravstvenim delavcem.
Out of the 4 JETREA patients with acute visual acuity decrease, 3 recovered following vitrectomy. 
Od 4 bolnikov z akutnim zmanjšanjem ostrine vida, zdravljenih z zdravilom JETREA, je pri 3 prišlo do izboljšanja po vitrektomiji.
Concentrate for solution for injection (sterile concentrate). 
Koncentrat za raztopino za injiciranje (sterilni koncentrat).
Information about storage and the time to use Jetrea once it has been thawed are described in the section intended for healthcare professionals only. 
Informacije o shranjevanju in času, v katerem je treba uporabiti zdravilo Jetrea potem, ko je bilo odmrznjeno, so opisane v poglavju, ki je namenjeno samo zdravstvenim delavcem.
The systemic toxicity of ocriplasmin has been evaluated in both rat and dog. 
Sistemsko toksičnost okriplazmina so ocenili pri podganah in psih.
Very common Retinogram abnormal*, colour vision test abnormal† 
Zelo pogosti nenormalen retinogram*, nenormalen izvid testa barvnega vida†
Intravitreal use after dilution 
intravitrealna uporaba po razredčenju
Fertility There are no data on the effect of JETREA on fertility. 
Plodnost Podatkov o vplivu zdravila JETREA na plodnost ni.
Therefore administration to both eyes concurrently is not recommended. 
Sočasnega dajanja v obe očesi zato ne priporočamo.
There is no experience of using Jetrea in pregnant women or during breast-feeding. 
Izkušenj z uporabo zdravila Jetrea pri nosečnicah ali doječih materah ni.
At Month 24, 51.4% of JETREA patients had a ≥ 5 points improvement in VFQ-25 composite score compared to 30.1% in the sham group. 
V 24. mesecu je imelo 51,4 % bolnikov iz skupine, zdravljene z zdravilom JETREA, izboljšanje za ≥ 5 točk pri skupnem seštevku na lestvici VFQ-25, v primerjavi s 30,1 % iz skupine z navideznim zdravljenjem.
Jetrea is used to treat adults with an eye disease called vitreomacular traction (VMT), including when it is associated with a small hole in the macula (central part of the light-sensitive layer at the back of the eye). 
Zdravilo Jetrea se uporablja za zdravljenje odraslih z očesno boleznijo, imenovano vitreomakularna trakcija (VMT), tudi v primeru, ko je povezana z majhno odprtino v makuli (osrednjem delu na svetlobo občutljive plasti v ozadju očesa).
Remove the vial from the freezer and allow to thaw at room temperature (takes about 2 minutes). 
Vialo vzemite iz zamrzovalnika in pustite, da se odtaja pri sobni temperaturi (kar traja približno
The intravitreal toxicity of ocriplasmin has been evaluated in rabbits, monkeys and minipigs. 
Intravitrealno toksičnost okriplazmina so ocenili pri kuncih, opicah in pritlikavih prašičih.
One case of accidental overdose of 0.250 mg ocriplasmin (twice the recommended dose) has been reported. 
Poročali so o enem primeru nenamernega prevelikega odmerka 0,250 mg okriplazmina (dvakratni priporočeni odmerek).
• Summary of Product Characteristics (SmPC) • Information packs for the patients 
• povzetkom glavnih značilnosti zdravila (SmPC)
- The active substance is ocriplasmin. 
- Zdravilna učinkovina je okriplazmin.
• How to prepare for Jetrea treatment 
• Kako se pripravite na zdravljenje z zdravilom Jetrea
Study TG-MV-014 
Študija TG-MV-014
5) events occurring pre-vitrectomy † using the Roth 28-hue colour vision test. See also section 4.4. 
5) dogodki pred vitrektomijo † z uporabo Rothovega testa barvnega vida z 28 barvami.
The incidence of retinal detachment that occurred pre-vitrectomy was 0.4% in the JETREA group and none in the placebo group, while the incidence of retinal tears (without detachment) that occurred pre-vitrectomy was 0.2% in the JETREA group and 0.5% in the placebo group. 
Incidenca odstopa mrežnice, ki se je pojavila pred vitrektomijo, je bila 0,4 % za skupino z zdravilom JETREA in nič za skupino s placebom, medtem ko je bila incidenca raztrganja mrežnice (brez odstopa), ki se je pojavila pred vitrektomijo, 0,2 % za skupino z zdravilom JETREA in 0,5 % za skupino s placebom.
If any of the above events occur the patient should be treated according to standard medical practice. 
Če se pojavi kar koli od zgoraj navedenega, je treba bolnika zdraviti v skladu s standardno zdravstveno prakso.
This effect was maintained over time and VMA resolution was consistently greater in the JETREA group at each post-injection study visit compared with the sham group. 
Ta učinek se je tudi ohranjal skozi čas in odprava VMA v skupini, zdravljeni z zdravilom JETREA, je bila pri vsakem obisku po injiciranju zdravila v študiji večja kot pri skupini z navideznim zdravljenjem.
The difference for improvement in the general vision sub-scale score was statistically significant (6.1 JETREA vs. 2.1 placebo, p=0.024). 
Statistično značilno razliko so opazili za izboljšanje podseštevka za splošni vid (6,1 za zdravilo JETREA v primerjavi z 2,1 za placebo, p = 0,024).
The periocular skin, eyelid and ocular surface should be disinfected and adequate anaesthesia and a broad spectrum topical microbiocide should be administered prior to the injection according to standard medical practice. 
Pred injiciranjem morajo biti koža okrog oči, veke ter površina očesa dezinficirani in bolnik mora dobiti ustrezno anestezijo in topikalni širokospektralni mikrobiocid v skladu s standardno zdravstveno prakso.
The difference was maintained from Day 7 through Month 6 
Razlika se je ohranila od 7. dne do 6. meseca (slika 1).
Once removed from the freezer or refrigerator, the medicinal product may be kept below 25 °C for up to 8 hours. 
Ko zdravilo vzamete iz zamrzovalnika ali hladilnika, ga lahko shranjujete pri temperaturi do 25 °C do
Beyond the central area, abnormal aspects of the IS/OS band attributed to JETREA have been observed in up to 10% of patients. 
Zunaj centralnega dela so pri do 10 % bolnikov opazili nenormalne značilnosti traka IS/OS, ki so jih pripisali zdravilu JETREA.
VMT is caused by traction resulting from a persistent attachment of the vitreous humour (jelly-like material in the back of the eye) to the macula. 
Vitreomakularno trakcijo povzroči vlek, ki nastane zaradi dolgotrajne povezanosti steklovine (gelu podobne snovi v ozadju očesa) z makulo.
The main reasons for vitrectomy were retinal detachment and retinopathy of prematurity. 
Glavna razloga za vitrektomijo sta bila odstop mrežnice in retinopatija nedonošenčkov.
Patients with a smaller VMA diameter at baseline (≤ 1500 microns) were more likely to achieve VMA resolution at Day 28 compared with those who had a diameter > 1500 microns. 
Bolniki z manjšim premerom VMA v izhodišču študije (≤ 1500 mikronov) so z večjo verjetnostjo dosegli odpravo VMA ob 28. dnevu v primerjavi s tistimi, ki so imeli premer > 1500 mikronov.
At all post-injection days, p≤0.024 in TG-MV-006, p≤0.009 in TG-MV-007, p<0.001 
Pri v seh dneh po injiciranju, p ≤0,024 za študijo TG-MV-006, p ≤0,009 za študijo TG-MV-007, p <0,001 za integrirane podatke
The patient also developed mild conjunctival hyperaemia, eye inflammation and miosis which resolved with corticosteroid eye drops. 
Pri bolniku so se pojavili tudi blaga hiperemija očesne veznice, vnetje očesa in mioza, ki so po uporabi kortikosteroidnih kapljic za oko izzveneli.
Because of the small dose administered (0.125 mg), detectable levels of ocriplasmin in systemic circulation are not expected after intravitreal injection. 
Zaradi majhnega uporabljenega odmerka (0,125 mg) ni pričakovati, da bi bile po intravitrealnem injiciranju v sistemskem obtoku zaznavne ravni okriplazmina.
Very common side effects (may affect more than 1 in 10 patients): - dark floating spots in the field of vision (floaters) - eye pain - bleeding on the surface of the eye - colour vision changes 
Zelo pogosti neželeni učinki (pojavijo se lahko pri več kot 1 od 10 bolnikov): - temne plavajoče lise v vidnem polju (lebdeči delci) - očesna bolečina - krvavitev na površini očesa
Tell your doctor/ophthalmologist if you have or have had any eye conditions or eye treatments. 
Obvestite svojega zdravnika/oftalmologa, če imate ali ste imeli katero koli očesno bolezen ali so vam zdravili oko.
After opening/dilution 
Po odprtju/redčenju
Only 0.1 mL of the total 0.3 mL solution in the vial should be administered. 
Dati morate le 0,1 ml od skupno 0,3 ml raztopine v viali.
The efficacy of JETREA has been further confirmed in a randomised, double-masked, shamcontrolled, 24-month study in patients with VMT finalised since the initial marketing authorisation approval. 
Učinkovitost zdravila JETREA je bila dodatno potrjena v randomizirani, dvojno slepi, z navideznim zdravljenjem kontrolirani, 24-mesečni študiji pri bolnikih z VMT, ki je bila zaključena v času po pridobitvi dovoljenja za promet z zdravilom.
Studies TG-MV-006 and TG MV-007 
Študiji TG-MV-006 in TG MV-007
Intravitreal injections have been associated with intraocular inflammation/infection, intraocular haemorrhage and increased intraocular pressure (IOP). 
Intravitrealno injiciranje je lahko povezano z intraokularnim vnetjem/okužbo, intraokularno krvavitvijo in zvišanim očesnim tlakom.
The proportion of patients who underwent vitrectomy for an event of VMA/VMT was 8.3% in the JETREA group compared to 19.2% in the sham group. 
Delež bolnikov, pri katerih je bila opravljena vitrektomija zaradi dogodka VMA/VMT, je bil 8,3 % v skupini, zdravljeni z zdravilom JETREA, v primerjavi z 19,2 % v skupini z navideznim zdravljenjem.
In both pivotal studies, the proportion of patients who achieved VMA resolution at Day 28 (primary endpoint) was significantly (p≤0.003) higher in the JETREA group compared with the placebo group. 
V obeh osrednjih študijah je bil delež bolnikov, pri katerih je bila ob 28. dnevu dosežena odprava VMA (primarni cilj študije), pomembno višji (p ≤0,003) v skupini z zdravilom JETREA v primerjavi s skupino s placebom.
Of these, 30% of JETREA treated patients and 15.4% of patients in the sham group experienced non-surgical FTMH closure at Month 24. 
Od teh je imelo 30 % bolnikov, zdravljenih z zdravilom JETREA, in 15,4 % bolnikov iz skupine z navideznim zdravljenjem nekirurško zaprtje FTMH v 24. mesecu, pri vseh pa se je to zgodilo do 3. meseca.
0.3 mL solution in a vial (type I glass) closed with a chlorobutyl rubber stopper and a blue polypropylene flip-off cap. 
0,3 ml raztopine v viali (steklo tipa I), zaprti s klorobutilnim gumijastim zamaškom in modro polipropilensko odmično zaporko.
Treatment with JETREA in the other eye is not recommended concurrently or within 7 days of the initial injection in order to monitor the post-injection course including the potential for decreased vision in the injected eye. 
Sočasno zdravljenje drugega očesa z zdravilom JETREA ali zdravljenje drugega očesa v 7 dneh po začetni injekciji ni priporočljivo, zato da lahko spremljamo potek po injiciranju, vključno z možnim poslabšanjem vida injiciranega očesa.
For handling of the medicinal product, see section 6.6. 
Za navodila glede ravnanja z zdravilom glejte poglavje 6.6.
The remaining sodium chloride 9 mg/mL (0.9%) solution for injection should be discarded. 
Preostalo raztopino 0,9-odstotnega natrijevega klorida (9 mg/ml) za injiciranje zavrzite.
In the JETREA group, 1 patient (0.7%) developed retinal tear and retinal detachment between Day 0 and Day 7 post-injection. 
V skupini z zdravilom JETREA pa sta se pri enem bolniku (0,7 %) pojavila raztrganje mrežnice in odstop mrežnice med dnevom 0 in 7. dnevom po injiciranju.
However, after treatment, a higher proportion of patients in the JETREA group had a change from an intact IS/OS band at baseline to an incomplete IS/OS band in the central area at a later time point compared with the sham group (7.7% and 2.8%, respectively at Day 28). 
Vendar se je po zdravljenju pri večjem odstotku bolnikov iz skupine, ki je prejemala zdravilo JETREA, v izhodišču popoln trak IS/OS v centralnem delu v poznejši časovni točki spremenil v nepopolnega, v primerjavi s skupino, ki je prejemala navidezno zdravljenje (7,7 % oziroma 2,8 % na 28. dan).
Early progression rates of full-thickness macular hole (until Day 7 post-injection) at RPE (retinal pigment epithelium) level were higher in the JETREA treated patients compared to sham or placebo. 
Pogostnosti zgodnjega napredovanja foramna makule, ki je zajemal vse plasti mrežnice (do 7. dne po injiciranju) do ravni RPE (retinalnega pigmentnega epitelija) so bile višje v skupini bolnikov, zdravljenih z zdravilom JETREA, kot pri bolnikih, zdravljenih navidezno ali s placebom.
Inject 0.1 mL of the diluted solution immediately into the mid-vitreous as it contains no preservatives. 
Takoj injicirajte 0,1 ml razredčene raztopine v sredino steklovine, saj ne vsebuje konzervansov.
3) including cystoid macular oedema 
3) vključno s cistoidnim makularnim edemom
In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products, other than sterile, preservative-free, non-buffered diluent sodium chloride 9 mg/mL (0.9%) solution for injection. 
Zaradi pomanjkanja študij kompatibilnosti zdravila ne smemo mešati z drugimi zdravili, razen s sterilno raztopino 0,9-odstotnega natrijevega klorida (9 mg/ml) za injiciranje brez konzervansov in pufrov.
0.2 mL solution in a vial (type I glass) closed with a chlorobutyl rubber stopper and an orange polypropylene flip-off cap. 
0,2 ml raztopine v viali (steklo tipa I), zaprti s klorobutilnim gumijastim zamaškom in oranžno polipropilensko odmično zaporko.
No dose adjustment or special considerations are anticipated for patients with hepatic impairment (see section 5.2). 
Prilagajanje odmerka ali posebni ukrepi za bolnike z okvaro ledvic niso potrebni (glejte poglavje 5.2).
- A severe decrease in vision has been reported in up to 1 in 10 patients within one week after Jetrea treatment. 
- Pri največ 1 od 10 bolnikov so v enem tednu po zdravljenju z zdravilom Jetrea opazili hudo poslabšanje vida.
The diluent should be withdrawn from an unopened container which should be used only once. 
Vehikel izvlecite iz zaprtega vsebnika, ki ga uporabite le enkrat.
Treatment is not recommended in such patients. 
Pri teh bolnikih se zdravljenje odsvetuje.
The new in-use expiry date should be calculated and noted on the carton before it is placed in the refrigerator. 
Preden date zdravilo v hladilnik, morate izračunati nov datum roka uporabnosti in ga zabeležiti na škatli.
Some tests and imaging of the back of the eye (retina) have been found to be abnormal after Jetrea administration. 
Izvidi nekaterih preiskav in slikanja očesnega ozadja (mrežnice) so bili po dajanju zdravila Jetrea nenormalni.
After Jetrea treatment you may experience some decrease in vision for a limited amount of time. 
Po zdravljenju z zdravilom Jetrea bo vaš vid morda nekaj časa slabši.
For storage conditions after thawing and opening/dilution of the medicinal product, see section 6.3. 
Za pogoje shranjevanja po odmrznitvi in odprtju/redčenju zdravila glejte poglavje 6.3.
The proportion of patients who gained ≥ 2 or ≥ 3 lines in BCVA at Month 6, irrespective of vitrectomy, was slightly higher in the JETREA group (36.2%, 18.6%) than in the sham group (28.6%, 13.1%). 
Delež bolnikov, ki so pridobili ≥ 2 ali ≥ 3 vrstice pri BCVA v 6. mesecu ne glede na izvedbo vitrektomije, je bil nekoliko večji v skupini, zdravljeni z zdravilom JETREA (36,2 %, 18,6 %), kot pa v skupini z navideznim zdravljenjem (28,6 %, 13,1 %).
Of these, the proportion of patients who achieved FTMH closure without vitrectomy at Day 28 was higher in the JETREA group than the placebo group (40.6% vs. 10.6%, respectively; p<0.001). 
Med njimi je bil delež bolnikov, ki je dosegel zaprtje FTMH brez vitrektomije na 28. dan, višji v skupini z zdravilom JETREA kot v skupini s placebom (40,6 % v primerjavi z 10,6 %; p <0,001).
JETREA 0.375 mg/0.3 mL solution for injection is a ‘ready-diluted' formulation, no further dilution is required. 
Zdravilo JETREA 0,375 mg/0,3 ml raztopina za injiciranje je že razredčena oblika in ne zahteva nadaljnjega redčenja.
What Jetrea looks like and contents of the pack 
Izgled zdravila Jetrea in vsebina pakiranja